Lua Labs Report - Hashimoto as an Integrative Model of Hormonal Autoimmunity

Date: 2026-06-10 Researcher: Lua Labs Classification: Neuroendocrine + Immuno-endocrine + Microbiome Line: L3 - Thyroid Axis and Reproductive Function Subtopic: 3.6 - Hashimoto's thyroiditis as a model of hormonal autoimmunity: lessons for the reproductive axis

External Sources

1. Unuane D, Velkeniers B, Poppe KG. (2026). "Thyroid disorders and female infertility." Journal of Clinical Endocrinology & Metabolism, 111(5):e1239-e1251. DOI: 10.1210/clinem/dgag039. URL: https://academic.oup.com/jcem/article-pdf/111/5/e1239/66725683/dgag039.pdf
2. Wang L, Zhu X, Xu S, Zhou B, Wu Y, Li Z, Zhao Y, Li S, Cheng F, Zhu L. (2026). "Hashimoto's thyroiditis: from pathogenesis to clinical management." Frontiers in Endocrinology, 17:1729316. DOI: 10.3389/fendo.2026.1729316. URL: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1729316/full
3. Gong B, Meng F, Wang X, Han Y, Yang W, Wang C, Shan Z, et al. (2024). "Effects of iodine intake on gut microbiota and gut metabolites in Hashimoto thyroiditis-diseased humans and mice." Communications Biology, 7:136. DOI: 10.1038/s42003-024-05813-6. URL: https://www.nature.com/articles/s42003-024-05813-6
4. Practice Committee of the American Society for Reproductive Medicine. (2024). "Subclinical hypothyroidism in the infertile female population: a guideline." Fertility and Sterility, 121(5):765-782. PMID: 38163620. URL: https://www.asrm.org/practice-guidance/practice-committee-documents/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline/
5. Popa EC, Maghiar L, Maghiar TA, Brihan I, Georgescu LM, Toderaș BA, Sachelarie L, Hurjui LL, Huniadi A. (2025). "Hashimoto's Thyroiditis and Female Infertility: A Clinical and Statistical Investigation of Endocrine and Ovarian Markers." Journal of Clinical Medicine, 14(13):4770. DOI: 10.3390/jcm14134770. URL: https://www.mdpi.com/2077-0383/14/13/4770
6. Łebkowska A, Krentowska A, Adamska A, Uruska A, Rogowicz-Frontczak A, Araszkiewicz A, Ożegowska K, Leśniewska M, Sowa P, Wender-Ożegowska E, Zozulińska-Ziółkiewicz D, Kowalska I. (2024). "The association of thyroid autoimmunity with ovarian reserve in women with type 1 diabetes with and without polycystic ovary syndrome." Scientific Reports, 14:13223. DOI: 10.1038/s41598-024-63741-1. URL: https://www.nature.com/articles/s41598-024-63741-1
7. van Dijk MM, Vissenberg R, Fliers E, van der Post JAM, van der Hoorn MLP, de Weerd S, et al. (2022). "Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial)." The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(22)00045-6. PMID: 35298917.
8. Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, et al. (2019). "Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception." New England Journal of Medicine, 380:1316-1325. DOI: 10.1056/NEJMoa1812537.
9. Romitti M, Fabris VC, Ziegelmann PK, Maia AL, Spritzer PM. (2018). "Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis." Endocrine Connections, 7(11):1158-1167. DOI: 10.1530/EC-18-0309. PMID: 30352422.

Base Knowledge (what I know before searching)

Hashimoto is not "high anti-TPO" or "high TSH" in isolation. It is an organ-specific autoimmune disease with thyroid lymphocytic infiltration, antibodies against TPO and/or thyroglobulin, progressive thyrocyte damage, ultrasound changes, and, over time, variable loss of T4/T3 output. The point that matters for L3.6 is distinguishing four states that public conversation often mixes together: (1) isolated anti-TPO with normal TSH/fT4 and no clinical evidence of thyroiditis; (2) euthyroid thyroid autoimmunity with positive TgAb/TPOAb and perhaps compatible ultrasound; (3) subclinical Hashimoto, where the gland still maintains fT4 but requires higher TSH; (4) clinical Hashimoto with overt hypothyroidism. Each state has different reproductive implications.

Biochemically, TPO sits at the apical edge of the thyrocyte and catalyzes iodide organification onto thyroglobulin using H2O2 generated by DUOX2. This makes it vulnerable: it is an exposed, oxidative, and highly immunogenic enzyme when there is excess iodine, insufficient selenium/GPx, epithelial damage, local inflammation, or increased antigen presentation. Anti-TPO can fix complement and mediate ADCC, but it is also a flag for a broader immune ecosystem: high Th1/Th17, low Treg, activated B-cells, thyroid inflammation, and HLA/CTLA4/PTPN22 susceptibility. In other words, isolated anti-TPO can be a marker; clinical Hashimoto is tissue already entering failure.

The reproductive axis does not suffer through a single mechanism. If tissue T3 drops, granulosa loses efficiency in response to FSH, CYP19A1, and steroidogenesis; the corpus luteum loses support for StAR, CYP11A1, and HSD3B; the endometrium loses part of HOXA10/LIF/integrins; the liver reduces SHBG if IR is added. If autoimmunity is also active, damage from cytokines, complement, subclinical oophoritis, TPO/ZP3 cross-reactivity, and altered follicular environment are added. This is why giving levothyroxine to a euthyroid anti-TPO+ woman does not automatically solve fertility: it corrects the hormonal arm if one exists, but not necessarily the immune arm.

Before searching, my model was: Hashimoto serves as a general model of hormonal autoimmunity because it shows how an endocrine gland can be "normal in labs" and still have an altered immune system affecting the ovary, endometrium, metabolism, and symptoms. The specific question for recent papers was: what new evidence separates isolated anti-TPO from functional Hashimoto, and what mechanisms connect iodine, microbiome, Th17/Treg, IR/PCOS, and reproduction?

Findings from Recent Papers

Unuane, Velkeniers, and Poppe 2026 synthesize the current state with an uncomfortable but useful conclusion: overt hypothyroidism clearly alters fertility; subclinical hypothyroidism and euthyroid thyroid autoimmunity remain a gray zone. The paper emphasizes that the use of TSH 2.5 mIU/L thresholds to define and treat preconception SCH has been broader than the evidence supporting it, and that the modern decision moves toward individual evaluation of thyroid function, antibodies, and reproductive context. The corollary is that the goal should not be "positive anti-TPO = intervention," but to stratify phenotypes.

The ASRM 2024 guideline grounds the clinical controversy: there is real debate over definition, screening, and treatment of SCH in infertility. It reports the classic definition of SCH as TSH above the normal range with normal fT4, and recognizes that TSH >2.5 or antithyroid antibodies do not always predict fecundity, pregnancy loss, or live birth in specific cohorts. In parallel, TABLET 2019 and T4LIFE 2022 showed that preconception levothyroxine in euthyroid TPOAb+ women did not increase live births. For Lua Labs, those results do not "deny" the harm of autoimmunity; they say isolated anti-TPO should not be confused with a hormonal deficit correctable by one molecule.

Wang et al. 2026 summarizes Hashimoto as a dynamic interaction among immune intolerance, genetic predisposition, and environmental triggers, with presentation ranging from asymptomatic subclinical status to significant hypothyroidism. The same article notes positive TPOAb in approximately 95% of patients with Hashimoto and underscores that, in the absence of thyroid functional changes, clinical management is usually follow-up, not automatic replacement. This distinction matters: isolated anti-TPO may be a trajectory alert; subclinical Hashimoto is already a system compensated by TSH; clinical Hashimoto is output loss.

Gong et al. 2024 provides the most valuable mechanism for closing L3: iodine, microbiome, and Th17/Treg are not three separate topics. In humans, they compared 23 initially untreated HT patients and 25 controls; they found changes in microbiota and metabolism, especially butanoate, and lower serum butyrate in HT. In NOD.H-2h4 mice, iodine altered microbiota and metabolites; iodine excess increased LPS, altered the intestinal barrier, reduced butyrate, and imbalanced Th17/Treg. Exogenous butyrate relieved lymphocytic infiltration and rebalanced Treg/Th17. This paper directly connects L3.5 with L1 and L2: excess iodine can damage not only through thyroid antigenicity, but by degrading the microbial-immune buffer.

Popa et al. 2025, although small and retrospective (86 women, 49 HT), shows the pattern we care about: mean differences in AMH and oocytes did not reach significance, but TSH correlated negatively with blastocyst formation (p=0.03), and the HT group showed subtle signals of lower reproductive performance. Łebkowska et al. 2024 in T1DM/PCOS works as a counterweight: TPOAb did not predict AMH or ovarian reserve in that cohort, and daily insulin dose was the predictor of AMH. This forces us not to overstate isolated anti-TPO. My reading: damage appears when anti-TPO coincides with functional thyroid burden, age, IR/PCOS, iodine extremes, inflammation, or buffer failure.

Complete Molecular/Endocrine Mechanism

Hashimoto as an integrative model has four layers. The first is the local thyroid layer:

Dietary iodide
  ↓ NIS/SLC5A5
Thyrocyte + TPO + DUOX2/H2O2 + TG
  ↓
Organification and MIT/DIT coupling
  ↓
T4/T3 output
  ↓
If iodine excess + low selenium/GPx + HLA susceptibility
  ↓
More iodinated Tg + ROS + thyrocyte apoptosis/pyroptosis
  ↓
TPO/Tg presentation → TPOAb/TgAb → complement/ADCC
  ↓
Subclinical or clinical Hashimoto

The second is the systemic immune layer:

Dysbiosis + LPS + altered intestinal barrier
  ↓
TLR4 / dendritic cells / low-grade inflammation
  ↓
Th17↑ + Treg↓ + IL-17/TNFα/IFNγ↑
  ↓
Thyroid autoantibodies + thyroid infiltrate
  ↓
Bystander damage in follicle/endometrium if the immune system is already activated
                                         ↓
                              Modulated by dietary diversity and fermentable-fiber patterns/vagal-tone phenotype (L1) and diurnal cortisol phenotype (L2)

The third is the functional reproductive layer:

Subclinical/clinical Hashimoto
  ↓
TSH↑ + normal/low fT4 + variable tissue T3
  ↓ DIO2/DIO1
T3 in granulosa/corpus luteum/endometrium
  ↓
CYP19A1 + StAR/CYP11A1/HSD3B + HOXA10/LIF/integrins
  ↓
Follicular E2, luteal P4, endometrial receptivity
  ↓
thyroid-symptom phenotype↑ + luteal-thyroid phenotype↑ + spotting + weak luteal phase + functional subfertility

The fourth is the metabolic-autoimmune layer, where PCOS/IR and Hashimoto potentiate each other:

IR / hyperinsulinemia
  ↓
SHBG↓ + LH/theca CYP17A1↑ + free androgens↑
  ↓
Anovulation / low P4 / unopposed E2
  ↓
Th17/Treg skew + adipose inflammation + altered leptin/TRH
  ↓
thyroid-autoimmune phenotype↑ + metabolic-reproductive phenotype↑ + higher probability of PCOS-Hashimoto overlap

The result is not a straight line. It is a circuit of gates. Isolated anti-TPO opens the possibility of the immune gate; high TSH opens the functional gate; iodine extremes open the environmental gate; IR/PCOS opens the metabolic gate; cortisol and sleep open the allostatic gate. Hashimoto appears when several gates remain open long enough.

Cross-Synthesis with Previous Findings

• L3.1 thyroid-symptom phenotype: L3.6 turns the thyroid-symptom phenotype into a functional signal within a larger entity. The question is no longer "are there thyroid symptoms?" but "are the thyroid symptoms stable, fluctuating, or phase-dependent, and do they coincide with anti-TPO/TSH/iodine/IR?" A high thyroid-symptom phenotype without anti-TPO may be functional subclinical hypothyroidism; the same phenotype with autoimmunity and extreme iodine exposure suggests a Hashimoto trajectory.

• L3.2 luteal-thyroid phenotype: Subclinical Hashimoto adds a persistent hit to the luteal phase. The luteal phase depends on local T3, P4, GR/PR, and endometrium. In Hashimoto, tissue T3 may be low; in active TAI, Th17/complement may reduce follicular quality; in high cortisol, DIO2 and PR desynchronize. luteal-thyroid phenotype becomes the most sensitive reproductive symptom of functional thyroid autoimmunity.

• L3.3 thyroid-autoimmune phenotype: L3.3 described TAI as a functional ovarian accelerator. L3.6 corrects the framing: thyroid-autoimmune phenotype should not treat isolated anti-TPO as a diagnosis. It should bifurcate: thyroid-autoimmune phenotype-Serologic (if anti-TPO/anti-Tg positive), thyroid-autoimmune phenotype-Functional (if thyroid-symptom phenotype/luteal-thyroid phenotype/TSH/fT4 are altered), thyroid-autoimmune phenotype-Systemic (autoimmune symptoms), thyroid-autoimmune phenotype-Trigger (iodine exposure/cortisol/microbiome).

• L3.4 metabolic-reproductive phenotype: Hashimoto and PCOS/IR are not random comorbidities. Romitti 2018 estimated OR 3.27 for Hashimoto in women with PCOS. L3.6 proposes that high metabolic-reproductive phenotype is an amplifier of thyroid-autoimmune phenotype: hyperinsulinemia and anovulation lower P4, raise inflammation, and favor Th17/Treg skew. In Valentina, isolated anti-TPO matters less than anti-TPO + metabolic-reproductive phenotype + oligomenorrhea.

• L3.5 iodine exposure: iodine stops being only a substrate. In L3.6, high iodine exposure enters as an autoimmune and microbial trigger: more TPO/TG antigenicity + lower butyrate + more Th17/Treg. Low iodine exposure enters as a functional trigger: marginal T4 + low tissue T3. Both may look like "Hashimoto" symptomatically, but one is antigenic pressure and the other is lack of substrate.

• L1 microbiome: Gong 2024 validates a strong connection with L1. Butyrate was already an axis of prebiotic-density phenotype/dietary-diversity phenotype; now it is also an immune buffer for Hashimoto. This makes the pattern "fermentable fiber + dietary diversity" not only estrobolome/progesterobolome, but immune tolerance.

• L2 cortisol and diurnal cortisol phenotype: chronic cortisol does not only interfere with DIO2 and PR. It also modulates immune tolerance. diurnal cortisol phenotype=A can precipitate functional thyroid symptoms with normal TSH through altered peripheral conversion; diurnal cortisol phenotype=B may be more inflammatory and autoimmune, with fatigue, infections, joint pain, and slow progression.

• L4 ovarian circadian coherence phenotype: Hashimoto can resemble perimenopause because TSH is circadian, fragmented sleep worsens symptoms, and AM/PM energy changes. Low ovarian circadian coherence phenotype can amplify thyroid-symptom phenotype and distort the clinical pattern: a user thinks "my thyroid is worse" when perhaps the clock worsened the perceived output.

Lua Labs Hypotheses

Hypothesis 29: Hashimoto Autoimmune Transition as a Multi-Axis Fingerprint

Statement: In LATAM women, the transition from isolated anti-TPO to functionally relevant Hashimoto occurs when high thyroid-autoimmune phenotype coincides with at least two amplifiers - extreme iodine exposure, sustained thyroid-symptom phenotype, high luteal-thyroid phenotype, high metabolic-reproductive phenotype, dysregulated diurnal cortisol phenotype, or low ovarian circadian coherence phenotype - and that pattern predicts more luteal-cycle irregularity and systemic symptoms than isolated anti-TPO by itself.

Proposed mechanism: Isolated anti-TPO marks broken tolerance, but not necessarily tissue damage or hormonal deficit. Progression requires pressure on the system:

Positive anti-TPO/TgAb or family history of TAI
  + high or low iodine exposure
  + low butyrate/vagal-tone phenotype/dietary-diversity phenotype buffer
  + dysregulated diurnal cortisol phenotype A/B
  + metabolic-reproductive phenotype or luteal-thyroid phenotype
  ↓
Exposed thyrocyte + Th17/Treg skew + variable tissue T3
  ↓
Functional Hashimoto: symptoms + altered luteal phase/cycle/metabolism

The original part is the change in diagnostic unit: Hashimoto is not modeled as an antibody, but as a multi-axis transition. Anti-TPO is a seed; Hashimoto transition phenotype is the ecosystem that decides whether it germinates clinically.

Confidence level: Medium. High for TPO/Hashimoto biology and for the euthyroid anti-TPO controversy; medium for the iodine-microbiome-Th17 axis per Gong 2024; medium-low for the multi-axis transition phenotype until validation.

How to validate:

• With a formal study: n=120 women 18-49, 12 months, TSH/fT4/fT3/anti-TPO/anti-Tg/Tg/AMH/HOMA-IR/SHBG/UIC at 3 timepoints, plus structured symptom diaries. Compare isolated anti-TPO vs a high multi-axis phenotype. Key prediction: the multi-axis phenotype predicts TSH slope or luteal-thyroid worsening better than baseline anti-TPO.

Limitations: Anti-TPO can fluctuate and does not always precede symptoms. The thyroid-autoimmune phenotype includes nonspecific symptoms. The "Hashimoto diagnosis" outcome depends on medical access. Estimated iodine exposure without urinary iodine (UIC) is a weak proxy. The hypothesis should be presented as risk stratification, not diagnosis.

Hypothesis 30: Treg-Butyrate Rescue Window in Perimenopausal Hashimoto

Statement: In Carmen (42-52) with perimenopausal transition and high thyroid-autoimmune phenotype/Hashimoto transition phenotype, the collapse of luteal P4 reduces immune tolerance just as iodine/IR/cortisol increase antigenic pressure; a phenotype with high dietary diversity and fermentable-fiber patterns/vagal-tone phenotype will have less Hashimoto-like symptomatic progression than a phenotype with low microbial buffers.

Proposed mechanism: Progesterone is not only reproductive; it has immunomodulatory effects that favor tolerance, Treg, and lower Th1/Th17 activation in reproductive windows. In perimenopause, P4 falls before E2, the luteal phase becomes erratic, and the corpus luteum becomes vulnerable to T3/cortisol. At the same time, perimenopausal IR, fragmented sleep, and variable iodine increase inflammation. If the microbiome produces sufficient butyrate, it can partially compensate for the loss of P4 tolerogenic signaling; if not, Th17/Treg tilts toward autoimmunity.

Early perimenopause
  ↓ luteal P4 + luteal-thyroid phenotype↑
  ↓
Low cyclic immune tolerance
  + extreme iodine exposure / metabolic-reproductive phenotype / diurnal cortisol phenotype-B / poor sleep
  ↓
Th17/Treg skew + rising anti-TPO/TgAb trajectory
  ↓
Hashimoto-like symptoms superimposed on perimenopause
       ↑
Butyrate/dietary diversity and fermentable-fiber patterns/vagal-tone phenotype cushion the immune transition

Confidence level: Low-Medium. P4-immunity and butyrate-Treg biology are solid; the perimenopausal window as a specific Hashimoto accelerator is original and requires longitudinal evidence.

How to validate:

• With a formal study: n=100 peri, 12 months, anti-TPO/anti-Tg/TSH/fT4/fT3, luteal progesterone or optional urinary PdG, optional fecal SCFAs, UIC, HOMA-IR. Prediction: low butyrate/low prebiotic-density phenotype + high luteal-thyroid phenotype predicts greater TPOAb/TSH rise.

Limitations: Perimenopause by itself produces fatigue, poor sleep, brain fog, and weight changes. Separating functional Hashimoto from perimenopause requires labs. Measuring luteal P4 is complicated if cycles are irregular.

Hypothesis 31: PCOS-Hashimoto as "double-entry hormonal autoimmunity"

Statement: In Valentina/Sofía with high metabolic-reproductive phenotype, functional Hashimoto risk does not depend only on autoimmune predisposition, but on a double entry: IR/anovulation lowers tolerogenic P4, and iodine/microbiome/cortisol raise immune pressure; the high metabolic-reproductive phenotype-thyroid-autoimmune phenotype phenotype will be more predictive of anti-TPO/Hashimoto than isolated thyroid-autoimmune phenotype.

Proposed mechanism: PCOS produces hyperandrogenism and IR; IR lowers SHBG, raises adipose inflammation, and favors leptin/TRH; anovulation reduces P4, and unopposed E2 alters immunity. Hashimoto contributes variable tissue T3, high TSH, and fatigue/slower metabolism. The combination creates a loop:

IR/PCOS → anovulation → low P4
      ↓                 ↓
Adipose inflammation    Low immune tolerance
      ↓                 ↓
Th17/Treg skew + thyroid-autoimmune phenotype↑ + Hashimoto susceptibility
      ↓
Low tissue T3 → SHBG↓ → metabolic-reproductive phenotype↑

Confidence level: Medium. PCOS-Hashimoto co-occurrence has meta-analysis support; the double-entry mechanism is Lua Labs synthesis.

How to validate:

• With a formal study: n=160 women 18-35, 2x2 groups high/low metabolic-reproductive phenotype and high/low thyroid-autoimmune phenotype. Labs: anti-TPO/TgAb, TSH/fT4/fT3, HOMA-IR, SHBG, free testosterone, AMH, ultrasound if available. Prediction: significant metabolic-reproductive phenotype x thyroid-autoimmune phenotype interaction for anti-TPO+ and high-normal TSH.

Limitations: PCOS increases AMH, while TAI/DOR may lower AMH; the marker becomes difficult to interpret. Hyperandrogenism and Hashimoto can indirectly share alopecia/fatigue. It requires avoiding diagnostic inference without clinical evaluation and laboratory testing.

Candidate Formulation

Name: Hashimoto Autoimmune Coherence Foundation (HACF), candidate formulation for research and education, not prescription.

Compounds / components:

• Calibrated dietary selenium: GPx and deiodinase cofactor; reduces oxidative stress from TPO organification. In Hashimoto, it should not be separated from iodine: low selenium + high iodine is an immunogenic combination.
• Vitamin D + VDR support: modulates Treg/Th17; especially relevant in high thyroid-autoimmune phenotype, family autoimmune history, and low sun exposure.
• Fermentable fiber / dietary butyrate: beans, nopal, oats, green banana, real nixtamal, chia; mechanism: SCFA → GPR43/GPR109A + HDAC inhibition → Treg and intestinal barrier.
• Dietary omega-3 and polyphenols: reduction of NF-kB/IL-17/TNFα; systemic anti-inflammatory arm.
• Iodine Exposure Mapping, not direct iodine: keep the L3.5 output. Exposure is stratified; supplementation is not recommended without biomarkers.
• Chrono-HPA foundation: regular sleep, AM light, caffeine, and late eating as diurnal cortisol phenotype/ovarian circadian coherence phenotype modulators; not as Hashimoto treatment, but as reduction of allostatic noise.
• Metabolic-IR branch: if metabolic-reproductive phenotype is high, prioritize low glycemic load, early protein/fiber, and strength training as a hypothesis for reducing inflammation/low SHBG.

Target population: Carmen with peri + high thyroid-autoimmune phenotype/Hashimoto transition phenotype; Valentina with high metabolic-reproductive phenotype-thyroid-autoimmune phenotype; Sofía with self-reported anti-TPO, irregular cycles, and thyroid symptoms. Rosa only as education for medical conversation, because the reproductive window has already closed and the focus would be cardiovascular, bone, and metabolic.

Complementary mechanisms: selenium reduces TPO oxidative stress; vitamin D and butyrate push Treg; omega-3/polyphenols lower inflammation; tracking estimated iodine exposure avoids the mistake of pushing excess iodine; the IR branch reduces leptin/TRH, low SHBG, and inflammation; the chrono-HPA branch reduces DIO2/GR noise.

Regulatory status: foods, habits, and education. It is not a therapeutic protocol, does not replace medical evaluation, and does not prescribe supplements or drugs.

Requires validation: formal 12-month study with TSH/fT4/fT3/anti-TPO/anti-Tg/UIC/HOMA-IR/SHBG/AMH and Hashimoto transition phenotype/estimated iodine exposure/metabolic-reproductive phenotype/luteal-thyroid phenotype scores. Without that validation, HACF is a hypothesis architecture, not a clinical recommendation.

Individual Variability

The same anti-TPO can be silent or clinically noisy depending on context:

• Immune genetics: HLA-DR3/DR5, CTLA4, PTPN22, FOXP3, STAT4 change the autoimmunity threshold.
• Thyroid genetics: DIO2 Thr92Ala, TG/TPO/DUOX2/NIS variants can alter conversion, antigenicity, and thyroid resilience.
• Iodine and selenium: high iodine with low selenium is more oxidative; low iodine with high DIO2/cortisol produces peripheral hypofunction.
• Hormonal stage: perimenopause lowers tolerogenic P4; postpartum immunity rebounds; an active cycle has variable tolerance windows.
• PCOS/IR: hyperinsulinemia, leptin, visceral adiposity, and low P4 from anovulation create baseline inflammation.
• Microbiome: low butyrate, low functional Bifidobacterium/Lactobacillus, low fiber, and antibiotics reduce Treg.
• Cortisol: diurnal cortisol phenotype=A pushes DIO2/GR noise; diurnal cortisol phenotype=B pushes basal inflammation and systemic fatigue.
• Chronobiology: irregular sleep and late eating increase noise in TSH, cortisol, insulin, and symptoms.
• Clinical access: a woman with frequent labs receives diagnosis earlier; another woman with the same biological state appears as "fatigue/perimenopause."